How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,654 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Serum microRNA-30c levels are correlated with disease progression in Xinjiang Uygur patients with chronic hepatitis B Full Text available with Trip Pro

Serum microRNA-30c levels are correlated with disease progression in Xinjiang Uygur patients with chronic hepatitis B We aimed to investigate the potential role and mechanism of microRNA-30c (miR-30c) in the pathological development of chronic hepatitis B (CHB). The serum levels of miR-30c in hepatitis B virus (HBV) carrier Xinjiang Uygur patients with inactive, low-replicative, high-replicative and HBe antigen-positive CHB were investigated. HepG2 cells were co-transfected with pHBV1.3 and miR (...) -30c mimic or inhibitor or scramble RNA. The effects of miR-30c dysregulation on HBV replication and gene expression, cell proliferation and cell cycle were then investigated. miR-30c was down-regulated in Xinjiang Uygur patients with CHB compared to healthy controls and its expression level discriminated HBV carrier patients with inactive, low-replicative, high-replicative and HBe antigen-positive risk for disease progression. Overexpression of miR-30c significantly inhibited HBV replication

2017 Brazilian Journal of Medical and Biological Research

82. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks Full Text available with Trip Pro

Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks Chronic infection with hepatitis B virus (HBV) progresses through multiple phases, including immune tolerant, immune active, immune control, and, in a subset of patients who achieve immune control, reactivation. The first, the immune tolerant phase, is considered to be prolonged in duration but essentially benign in nature, lacking long-term consequences, and thus not recommended for antiviral therapy. This review challenges the notion (...) that the immune tolerant phase is truly benign and considers the possibility that events during this phase may contribute significantly to cirrhosis, hepatocellular carcinoma (HCC), and the premature death of 25% of HBV carriers worldwide. Thus, earlier treatment than recommended by current guidelines should be considered. Low therapeutic coverage exacerbated by restrictive treatment guidelines may facilitate disease progression in many patients but also increase the risk of neonatal and horizontal

2017 Viruses

83. Association Between the Telomerase rs2736098_TT Genotype and a Lower Risk of Chronic Hepatitis B and Cirrhosis in Chinese Males Full Text available with Trip Pro

Association Between the Telomerase rs2736098_TT Genotype and a Lower Risk of Chronic Hepatitis B and Cirrhosis in Chinese Males Chronic hepatitis B (CHB) is caused by infection of hepatitis B virus (HBV) and liver cirrhosis (LC) is its most common complication. The accumulated evidence indicates a genetic context of HBV infection phenotypes. Here we determine a potential association of CHB/LC with the genetic variant of telomerase reverse transcriptase (TERT), a key player in aging including (...) : OR 2.398, 95% CI 1.168-4.922, P=0.02). Further analyses showed that the rs2736098_TT genotype difference occurred between male controls and patients (P=0.008) and male CT/CC-carriers exhibited highly increased risk of CHB compared to male controls (CT+CC vs TT, OR 3.182, 95% CI 1.350-7.500, P=0.01). There was no difference in the rs2736100 variants between controls and CHB patients. LTL was not different between cases and controls.The TERT rs2736098_TT genotype is associated with a lower CHB and LC

2017 Clinical and translational gastroenterology

84. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection Full Text available with Trip Pro

Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection The mechanisms of hepatitis B virus (HBV) persistent infection are not completely understood. Interleukin (IL)-35, which is a newly identified cytokine belongs to IL-12 family, has been demonstrated to induce immunotolerance. Thus, the aim of current study was to investigate the role of IL-35 during chronic HBV infection. A total of 61 patients with chronic HBV infection [37 chronic hepatitis B (CHB (...) ) and 24 asymptomatic HBV carriers (ASC)] and 20 healthy individuals were enrolled. IL-35 concentration as well as the modulatory function of IL-35 on CD4+CD25+CD127dim/- regulatory T cells (Tregs) and on HBV antigen-specific CD8+ T cells was investigated. IL-35 expression was significantly increased in both CHB and ASC, and was positively correlated with the levels of HBV DNA. Inhibition of viral replication induced the reduction in serum levels of IL-35. IL-35 stimulation led to inhibition

2017 Frontiers in cellular and infection microbiology

85. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. (Abstract)

Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. We investigated innate immune gene expression in clinical phases of chronic hepatitis B infection, including immune tolerant (IT), immune active (IA), inactive carrier (IC) and hepatitis B e antigen (HBeAg)-negative phases, as well as healthy controls. Expression levels of interferon types I, II and III, their receptor subunits, IRFs, TLRs and other IFN-induced genes in peripheral blood (...) expression levels of 23 genes were found in the IC phase. The highest mRNA expression levels of IFNs, IFN receptor subunits, IRFs and TLRs genes in all clinical phases were IFN-λ2 and 3, IFN-γR2, IRF7 and TLR7, and the lowest levels of mRNA expression were observed for IFN-α, IFN-λR1, IRF8 and TLR2. We conclude that innate immune response genes are expressed differentially among chronic HBV phases, and this difference may help to develop new precise and noninvasive methods to determine the progression

2017 Journal of viral hepatitis

86. The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: a review of published literature. (Abstract)

The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: a review of published literature. Chronic hepatitis B infection (CHB) causes up to 1.0 million deaths annually. Currently, more than 90% of CHB patients worldwide are receiving indefinite nucleos(t)ide analogue (NA) therapy. New strategies for optimizing hepatitis B surface antigen (HBsAg) loss are required for NA-treated patients as the majority are unable to achieve HBsAg loss and may require lifelong (...) therapy. In hepatitis B e antigen (HBeAg)-positive patients, switching from NAs to finite peginterferon (PegIFN) therapy can double HBeAg seroconversion rates. One in five patients who switch to PegIFN can achieve HBsAg loss, whereas patients who continue NA therapy typically do not. In HBeAg-negative NA-treated patients, add-on PegIFN therapy achieves higher, albeit modest, HBsAg loss rates compared with continued NA monotherapy and offers the opportunity for NA-treated patients to achieve

2017 Journal of viral hepatitis

87. Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent. Full Text available with Trip Pro

-3 expression and to investigate the manner in which the immune response is regulated to balance the strength of the response with the extent of liver injury in chronic HBV infection. The results showed that LAG-3 expression levels were significantly higher in CD8 T cells from chronic hepatitis B patients in the immune-active phase compared with chronic asymptomatic HBV carriers and healthy controls. CD8 T-cell function was suppressed in cells with high LAG-3 expression, and these cells exhibited (...) Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent. Weak or absent virus-specific CD8 T-cell responses to hepatitis B virus (HBV) infection are thought to be responsible for persistent HBV infection. Previous studies have indicated that multiple inhibitory receptors, including lymphocyte activation gene-3 (LAG-3), can suppress the CD8 T-cell response in chronic viral infection. This study aimed to detect LAG

2017 Medicine

88. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. (Abstract)

Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. Hepatitis B is one of the most common infectious diseases globally. It has been estimated that there are 350 million chronic hepatitis B virus (HBV) carriers worldwide. The liver is connected to the small intestine by the bile duct, which carries bile formed in the liver to the intestine. Nearly all of the blood that leaves the stomach and intestines must pass through (...) the liver. Human intestines contain a wide diversity of microbes, collectively termed the 'gut microbiota'. Gut microbiota play a significant role in host metabolic processes and host immune modulation, and influence host development and physiology (organ development). Altered gut microbiota is a common complication in liver disease. Changes in intestinal microbiota seem to play an important role in induction and promotion of HBV-induced chronic liver disease progression, and specific species among

2017 Journal of Hospital Infection

89. Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels Full Text available with Trip Pro

Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels We investigated whether long-term clinical outcomes such as disease progression or inactive hepatitis B virus (HBV) carrier state can be predicted by baseline factors in hepatitis B e antigen (HBeAg)-negative HBV infected patients with an elevated viral load.A retrospective cohort of 527 HBeAg-negative chronic HBV infected patients with an elevated viral load (...) independent risk factors for HCC. Low HBV DNA and quantitative hepatitis B surface antigen (qHBsAg) levels were independent predictors for becoming inactive carriers in patients without cirrhosis. In non-cirrhotic patients with both low qHBsAg and HBV DNA levels, the 5-year cumulative incidence of an inactive carrier was 39.8%, while that of disease progression was 1.6%.HBeAg negative patients without cirrhosis can be closely monitored for becoming an inactive carrier when both HBV DNA and qHBsAg levels

2015 PloS one

90. Hepatitis B and C testing: people at risk of infection

infectious disease and the Hepatitis B antenatal screening and newborn immunisation programme, both published by the Department of Health, and in the NICE guidance on Reducing the differences in the uptake of immunisations. Whose health will benefit? In the UK, the majority (95%) of new chronic hepatitis B infections occur in migrant populations, having been acquired perinatally in the country of birth. In contrast, approximately 90% of chronic hepatitis C infections are seen in people who inject drugs (...) or have done so in the past. Groups at increased risk of hepatitis B compared with the general UK population include: Hepatitis B and C testing: people at risk of infection (PH43) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 11 of 93People born or brought up in a country with an intermediate or high prevalence (2% or greater) of chronic hepatitis B. This includes all countries in Africa, Asia, the Caribbean

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

91. Hepatitis C Virus Modulates Solute carrier family 3 member 2 for Viral Propagation Full Text available with Trip Pro

Hepatitis C Virus Modulates Solute carrier family 3 member 2 for Viral Propagation Hepatitis C virus (HCV) exploits an extensive network of host proteins to maintain chronic infection. Using RNA-Seq technology, we identified 30 host genes that were differentially expressed in cell culture grown HCV (HCVcc)-infected cells. Of these candidate genes, we selected solute carrier family 3 member 2 (SLC3A2) for further investigation. SLC3A2, also known as CD98hc, is a member of the solute carrier

2018 Scientific reports

92. A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

Go to Brief Summary: CR-HepB registry started in June 30,2012 to collect HBV cases from general hospitals or specialized hospitals for infectious diseases in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. The main criteria for registration is HBsAg-positivity more than 6 months, and these patients will receive followed-up visits every three to six months. Condition or disease Chronic Hepatitis B Detailed Description: This web (...) ,registry,cirrhosis, HCC Additional relevant MeSH terms: Layout table for MeSH terms Hepatitis Hepatitis A Hepatitis, Chronic Hepatitis B Hepatitis B, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Hepadnaviridae Infections DNA Virus Infections

2017 Clinical Trials

93. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. Full Text available with Trip Pro

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. Hepatitis B virus (HBV) contains three viral surface proteins, large, middle and small hepatitis B surface protein (LHBs, MHBs, SHBs). Proportions of LHBs and MHBs are lower in patients with inactive vs active chronic infection. Interferon alfa may convert hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) to an inactive carrier state, but prediction (...) of sustained response is unsatisfactory. The aim of this study was to test the hypothesis that quantification of MHBs and LHBs may allow for a better prognosis of therapeutic response than total hepatitis B surface antigen (HBsAg) concentration.Hepatitis B surface proteins were measured before and during peginterferon alfa-2a therapy in serum from 127 Asian patients with HBeAg-positive CHB. Sustained response was defined as HBeAg seroconversion 24 weeks post-treatment.Mean total HBs levels were

2020 Liver International

94. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells Full Text available with Trip Pro

Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells Chronic Hepatitis B Virus (HBV) infection is linked to hepatocellular carcinoma (HCC) pathogenesis. Despite the availability of a HBV vaccine, current treatments for HCC are inadequate. Globally, 257 million people are chronic HBV carriers, and children born from HBV-infected mothers become chronic carriers, destined to develop liver cancer. Thus, new therapeutic approaches are needed to target essential (...) pathways involved in HCC pathogenesis. Accumulating evidence supports existence of hepatic cancer stem cells (hCSCs), which contribute to chemotherapy resistance and cancer recurrence after treatment or surgery. Understanding how hCSCs form will enable development of therapeutic strategies to prevent their formation. Recent studies have identified an epigenetic mechanism involving the downregulation of the chromatin modifying Polycomb Repressive Complex 2 (PRC2) during HBV infection, which results

2018 Genes

95. Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma Full Text available with Trip Pro

Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma The entire disease spectrum of chronic HBV infection (CHB) includes asymptomatic carriers (AC), active chronic hepatitis (ACH), cirrhosis (Cir), and hepatocellular carcinoma (HCC). Previous study have demonstrated that the costimulation profiles from the livers of patients influenced immune responses and played various immunological roles

2016 Hepatitis monthly

96. Pause for thought on the missing millions affected by hepatitis B: Are we doing enough? World Hepatitis Day – 28th July 2019

, such as those with links to endemic countries, but also people whose risk of infection include sexual exposure. 10,11 Yet, the epidemiology of hepatitis B infection remains poorly characterised in many countries, a problem compounded by the lack of systematic testing of those at risk and incomplete surveillance programs. 10 It is hardly surprising that globally fewer than 10% of chronic HBV carriers are aware of their status. Among those with a diagnosis, fewer than 10% are in appropriate care and receiving (...) doing enough to lift the heavy burden of hepatitis B? Worldwide, an estimated 257 million people have chronic hepatitis B virus (HBV) infection and one death every 30 seconds results from HBV-related complications – cirrhosis and liver cancer – totalling nearly a million deaths each year. 1-4 The global incidence of hepatocellular carcinoma continues to climb, with HBV infection as a leading cause. 5 In stark contrast, public health interventions over the past decades have sent incidence of many

2019 Sexually Transmitted Infections blog

97. Molecular characterization of hepatitis B virus among chronic hepatitis B patients from Pointe Noire, Republic of Congo Full Text available with Trip Pro

Molecular characterization of hepatitis B virus among chronic hepatitis B patients from Pointe Noire, Republic of Congo Chronic Hepatitis B infection is a major health problem in Republic of Congo therefore molecular analysis of HBV strains is important to detect the patients at high risk of disease progression.Serum samples were obtained from 111 chronic HBV patients in Pointe Noire. HBsAg, HBeAg and HBeAb were detected. A fragment of the preS1 region of HBV was amplified and sequenced (...) to determine genotypes, subgenotypes and to identify mutations.Of the 111 samples analyzed, 35 patients were asymptomatic carriers (ASC), 24 with a chronic active hepatitis (CAH), 33 with liver cirrhosis (LC) and 19 have a hepatocellular carcinoma (HCC). The mean age were 45 ± 13 year, 88 (79.3 %) were male and 23 (20.7 %) female. The prevalence of HBeAg was 15.3 % and 73 % of subjects were anti-HBe positive. The mean serum level of alanine aminotransferase transaminase (ALT) and aspartate transaminase

2016 Infectious agents and cancer

98. Fatigue in Patients with Chronic Hepatitis B living in North America: Results from the Hepatitis B Research Network (HBRN) Full Text available with Trip Pro

Fatigue in Patients with Chronic Hepatitis B living in North America: Results from the Hepatitis B Research Network (HBRN) Fatigue is a common symptom of liver disease but not well characterized in patients with chronic hepatitis B virus (HBV).We assessed the rate of fatigue using a validated instrument in patients with HBV and identified demographic, virologic, and clinical features associated with fatigue in a cross-sectional cohort study from the Hepatitis B Research Network.Participants (...) were English- and Spanish-speaking adults with chronic HBV who were not pregnant nor on treatment. Fatigue was measured using the PROMIS® Fatigue 7-item Short Form.The sample included 948 adults: median age 42; 51 % female; 71 % Asian; 74 % college educated; 77 % employed; 41 % inactive HBV carriers; 36 % with active chronic disease; and 2 % with advanced fibrosis, defined as AST-platelet ratio index (APRI) > 1.50. Patients with chronic HBV had a mean fatigue T-score of 46.8 ± SD = 7.9, compared

2016 Digestive diseases and sciences

99. Tenofovir alafenamide monotherapy for hepatitis B

. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is the most common chronic viral infection in the world and an estimated two billion people are infected, and more than 350 million people are chronic carriers of the virus. The likelihood that infection with the virus becomes chronic depends upon the age at which a person becomes infected: 80-90% of infants infected during the first year of life and 30-50% of children infected before the age of six develop (...) . 2015 Authors' objectives Tenofovir alafenamide is intended to be used as monotherapy for the treatment of chronic hepatitis B. Tenofovir alafenamide is a nucleotide analogue reverse transcriptase inhibitor (NtRTI) and a prodrug of tenofovir, with a potentially greater antiviral activity compared to the existing tenofovir preparation, tenofovir disoproxil fumarate. If licensed, tenofovir alafenamide monotherapy will provide an additional oral treatment option for patients with chronic hepatitis B

2015 Health Technology Assessment (HTA) Database.

100. Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg Full Text available with Trip Pro

Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg In a hepatitis B virus (HBV)‑infected population, persistently low expression levels of serum HBV serum antigen (HBsAg) are present, particularly in chronic asymptomatic HBV carriers (ASCs). The present study sequenced the HBV Pre‑S gene, and aimed to elucidate its features in ASCs with low HBsAg expression compared with in the established HBV Pre‑S reference gene sequences from ASCs with high HBsAg (...) clinical features of the population with low‑level HBsAg were as follows: Most were ASCs with chronic HBV infection; 97.1% were HBsAg/anti‑HBe/anti‑HBc‑positive; 82.54% carried the B genotype; and 84.13% displayed the adw serotype. The results indicated that there were novel and meaningful mutations, including co‑mutations, at numerous loci and sites in the Pre‑S gene, as well as deletion mutations in the Pre‑S2 gene. These mutations in the Pre‑S1 and Pre‑S2 gene fragments accounted for 65.38% (68/104

2018 International journal of molecular medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>